alexa A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
Oncology

Oncology

Chemotherapy: Open Access

Author(s): Eng C, Ramanathan RK, Wong MK, Remick SC, Dai L

Abstract Share this page

Abstract Gemcitabine is a commonly used chemotherapy for biliary tree carcinomas, achieving response rates of 10\% to 60\%. Preclinical studies indicate that fixed dose rate infusion optimizes accumulation of gemcitabine triphosphate and may enhance the clinical activity of gemcitabine. We conducted a phase II study of fixed dose rate gemcitabine in 15 chemotherapy-naive patients with advanced cholangiocarcinoma and gallbladder carcinoma. Gemcitabine was administered at a dose of 1500 mg/m2 over 150 minutes weekly for 3 weeks every 28 days. Fourteen patients were evaluable for response. No complete or partial responses were observed. Two patients (13\%) had stable disease lasting a median of 9 weeks. The median time to progression was 9 weeks; median survival was 20 weeks. There was considerable grade 3/4 hematologic toxicity, including neutropenia in 49\% of patients, leukopenia in 40\%, anemia in 27\%, and thrombocytopenia in 27\%. Grade 3/4 nonhematologic toxicities were minimal. We conclude that fixed dose rate gemcitabine results in significant myelosuppression and has minimal activity in patients with biliary tree carcinoma.

  • To read the full article Visit
  • Subscription
This article was published in Am J Clin Oncol and referenced in Chemotherapy: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords